The researchers looked at cardiac outcomes among a group of HER2+ breast cancer patients treated with trastuzumab who had an asymptomatic LVEF decline of < 50%.
HER2-Positive Breast Cancer
The study findings suggest that disease-free survival can continue to be used as a surrogate endpoint in the setting of early HER2+ breast cancer.
The Opti-HER HEART trial examined whether liposomal formulations of chemotherapy agents may reduce cardiac toxicity in HER2+ breast cancer patients.
Researchers tested whether combining trastuzumab/paclitaxel with dasatinib would have a high response rate in patients with metastatic HER2+ breast cancer.
Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.
In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity?
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer.
Researchers compared the cost effectiveness of two durations of trastuzumab in HER2+ breast cancer patients.
Dr. Adam Brufsky speaks with Cancer Network about the evolution and future of HER2-targeted therapy.
A subgroup analysis of Short-HER looked at the differences in 5-year DFS rates for 9 weeks vs 1 year of trastuzumab for HER2+ breast cancer patients.